Lercanidipine – unique, original hypotensive drug Review article
Article Sidebar
Published:
Dec 31, 2013
Keywords:
lercanidipine, arterial hypertension
Main Article Content
Abstract
Lercanidipine is a third-generation dihydropyridine calcium antagonist acting through the blockade of the L-type calcium channels in cell membranes. It is highly selective for vascular smooth muscle and has a high lipophilicity. A gradual onset of action explains why lercanidipine does not induce reflex tachycardia. In contrast to first and second generation of dihydropyridines, it induces peripheral edema with a lower incidence. The efficacy and tolerability of oryginal lercanidipine have been evaluated in several comparative and non-comparative studies. Recent data suggest that lercanidipine may have also renoprotective and anti-atherogenic effect. Other benefits reported with lercanidipine are favorable effects on glucose tolerance and fibrinolysis.
Article Details
How to Cite
Waszkiewicz, M., & Lewandowski , J. (2013). Lercanidipine – unique, original hypotensive drug. Medycyna Faktow (J EBM), 6(4(21), 36-43. Retrieved from https://www.journalsmededu.pl/index.php/jebm/article/view/2394
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Wytyczne ESH/ESC dotyczące postępowania w nadciśnieniu tętniczym w 2013 roku. Kardiol. Pol. 2013; 71(supl. III): S30-115.
2. Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych [online].
3. Messerli F.H.: Calcium antagonists in hypertension: from hemodynamics to outcomes. Am. J. Hypertens. 2002; 15: 94S-97S.
4. Barchielli M., Dolfini E., Farina P. et al.: Clinical pharmacokinetics of lercanidipine. J. Cardiovasc. Pharmacol. 1997; 29(Suppl. 2): S1-15.
5. Bang L.M., Chapman T.M., Goa K.L.: Lercanidipine: a review of its efficacy in the management of hypertension. Drugs 2003; 63: 2449-72.
6. Primacor. Charakterystyka produktu leczniczego.
7. Brown M., Moorman J., West D. et al.: Drugs in Context – Primary Care B. Cardiovascular Medicine II 2004: 117-52.
8. Suchanek R.: Porównanie leków oryginalnych i generycznych na przykładzie lerkanidypiny. Świat Med. Farm. 2013; 6(145): 4-12.
9. Borghi C.: Lercanidipine in hypertension. Vascular Health and Risk Management 2005; I(3): 173-182.
10. Barrios V., Escobar C., Navarro A. et al.: Lercanidipine is an effective and well tolerated antihypertensive drug regardless the cardiovascular risk profile: the LAURA Study. Int. Clin. J. Pract. 2006; 60(11): 1364-1370.
11. Lin T.H., Voon W.C., Yen H.W. et al.: Lercanidipine and Losartan Effects on Blood Pressure And Fibrinolytic Parameters. Kaohsiung J. Med. Sci. 2006; 22(4): 177-183.
12. Cherubini A., Fabris F., Ferrari E.: Comparative effects of lercanidipine, lacidipine, and nifedipine gastrointestinal therapeutic system on blood pressure and heart rate in elderly hypertensive patients: the ELderly and LErcanidipine (ELLE) study. Arch. Gerontol. Geriatr. 2003; 37: 203-212.
13. Chen T., Chen G., Yang T.: Efficacy and safety of the treatment: combination of benazepril/lercanidipine vs. benazepril alone in patients with mild-to-moderate hypertension. Chin. Med. J. 2013; 126(12): 2286-2290.
14. Barrios V., Escobar C., Rocio E.: Fixed combinations in the management of hypertension: perspectives on lercanidipine – enalapril. Vasc. Health Risk Manag. 2008; 4(4): 847-853.
15. Egan C.G., Pontremoli R.: Role of the fixed-dose combination lercanidipine-enalapril in renal protection. J. Nephrol. 2011; 24(04): 428-437.
16. Makarounas-Kirchmann K., Glover-Koudounas S., Ferrari P.: Results of a Meta-Analysis Comparing the Tolerability of Lercanidipine and Other Dihydropyridine Calcium Channel Blockers. Clinical Therapeutics 2009; 31: 1652-1663.
17. Basile J.: The Role of Existing and Newer Calcium Channel Blockers in the Treatment of Hypertension. J. Clin. Hypertens. 2004; IV(XI): 621-630.
18. Mackenzie I.S., McEniery C., Dhakam Z. et al.: Comparison of the Effects of Antihypertensive Agents on Central Blood Pressure and Arterial Stiffness in Isolated Systolic Hypertension. Hypertension 2009; 54: 409-413.
19. Pruijm M., Maillard M., Burnier M.: Patient adherence and the choice of antihypertensive drugs: focus on lercanidipine. Vasc. Health Risk Manag. 2008; 4(6): 1159-1166.
20. Millar-Craig M., Shaffu B., Greenough A. et al.: Lercanidipine vs lacidipine in isolated systolic hypertension. J. Hum. Hypertens. 2003; 17: 799-806.
21. Pedrinelli R., Dell’Omo G., Nuti M. et al.: Heterogeneous effect of calcium antagonists on leg edema: a comparison of amlodipine versus lercanidipine in hypertensive patients. J. Hypertens. 2003; 21: 1969-73.
22. Robles N.R., Ocon J., Gomez C.F. et al.: Lercanidipine in patients with chronic renal failure: the ZAFRA study. Ren. Fail. 2005; 27(1): 73-80.
23. Ciro A.: Active dose findings for lercanidipine in a double-blind, placebo controlled design in patients with mild-to-moderate hypertension. J. Cardiovasc. Pharmacol. 1997; 29(Suppl. 2): S26-30.
24. Lewandowski J.: Dlaczego w leczeniu chorych warto stosować oryginalne leki?
2. Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych [online].
3. Messerli F.H.: Calcium antagonists in hypertension: from hemodynamics to outcomes. Am. J. Hypertens. 2002; 15: 94S-97S.
4. Barchielli M., Dolfini E., Farina P. et al.: Clinical pharmacokinetics of lercanidipine. J. Cardiovasc. Pharmacol. 1997; 29(Suppl. 2): S1-15.
5. Bang L.M., Chapman T.M., Goa K.L.: Lercanidipine: a review of its efficacy in the management of hypertension. Drugs 2003; 63: 2449-72.
6. Primacor. Charakterystyka produktu leczniczego.
7. Brown M., Moorman J., West D. et al.: Drugs in Context – Primary Care B. Cardiovascular Medicine II 2004: 117-52.
8. Suchanek R.: Porównanie leków oryginalnych i generycznych na przykładzie lerkanidypiny. Świat Med. Farm. 2013; 6(145): 4-12.
9. Borghi C.: Lercanidipine in hypertension. Vascular Health and Risk Management 2005; I(3): 173-182.
10. Barrios V., Escobar C., Navarro A. et al.: Lercanidipine is an effective and well tolerated antihypertensive drug regardless the cardiovascular risk profile: the LAURA Study. Int. Clin. J. Pract. 2006; 60(11): 1364-1370.
11. Lin T.H., Voon W.C., Yen H.W. et al.: Lercanidipine and Losartan Effects on Blood Pressure And Fibrinolytic Parameters. Kaohsiung J. Med. Sci. 2006; 22(4): 177-183.
12. Cherubini A., Fabris F., Ferrari E.: Comparative effects of lercanidipine, lacidipine, and nifedipine gastrointestinal therapeutic system on blood pressure and heart rate in elderly hypertensive patients: the ELderly and LErcanidipine (ELLE) study. Arch. Gerontol. Geriatr. 2003; 37: 203-212.
13. Chen T., Chen G., Yang T.: Efficacy and safety of the treatment: combination of benazepril/lercanidipine vs. benazepril alone in patients with mild-to-moderate hypertension. Chin. Med. J. 2013; 126(12): 2286-2290.
14. Barrios V., Escobar C., Rocio E.: Fixed combinations in the management of hypertension: perspectives on lercanidipine – enalapril. Vasc. Health Risk Manag. 2008; 4(4): 847-853.
15. Egan C.G., Pontremoli R.: Role of the fixed-dose combination lercanidipine-enalapril in renal protection. J. Nephrol. 2011; 24(04): 428-437.
16. Makarounas-Kirchmann K., Glover-Koudounas S., Ferrari P.: Results of a Meta-Analysis Comparing the Tolerability of Lercanidipine and Other Dihydropyridine Calcium Channel Blockers. Clinical Therapeutics 2009; 31: 1652-1663.
17. Basile J.: The Role of Existing and Newer Calcium Channel Blockers in the Treatment of Hypertension. J. Clin. Hypertens. 2004; IV(XI): 621-630.
18. Mackenzie I.S., McEniery C., Dhakam Z. et al.: Comparison of the Effects of Antihypertensive Agents on Central Blood Pressure and Arterial Stiffness in Isolated Systolic Hypertension. Hypertension 2009; 54: 409-413.
19. Pruijm M., Maillard M., Burnier M.: Patient adherence and the choice of antihypertensive drugs: focus on lercanidipine. Vasc. Health Risk Manag. 2008; 4(6): 1159-1166.
20. Millar-Craig M., Shaffu B., Greenough A. et al.: Lercanidipine vs lacidipine in isolated systolic hypertension. J. Hum. Hypertens. 2003; 17: 799-806.
21. Pedrinelli R., Dell’Omo G., Nuti M. et al.: Heterogeneous effect of calcium antagonists on leg edema: a comparison of amlodipine versus lercanidipine in hypertensive patients. J. Hypertens. 2003; 21: 1969-73.
22. Robles N.R., Ocon J., Gomez C.F. et al.: Lercanidipine in patients with chronic renal failure: the ZAFRA study. Ren. Fail. 2005; 27(1): 73-80.
23. Ciro A.: Active dose findings for lercanidipine in a double-blind, placebo controlled design in patients with mild-to-moderate hypertension. J. Cardiovasc. Pharmacol. 1997; 29(Suppl. 2): S26-30.
24. Lewandowski J.: Dlaczego w leczeniu chorych warto stosować oryginalne leki?